[go: up one dir, main page]

CY1124173T1 - Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες - Google Patents

Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες

Info

Publication number
CY1124173T1
CY1124173T1 CY20211100444T CY211100444T CY1124173T1 CY 1124173 T1 CY1124173 T1 CY 1124173T1 CY 20211100444 T CY20211100444 T CY 20211100444T CY 211100444 T CY211100444 T CY 211100444T CY 1124173 T1 CY1124173 T1 CY 1124173T1
Authority
CY
Cyprus
Prior art keywords
methods
therapy
compositions
aminopurine compounds
compounds
Prior art date
Application number
CY20211100444T
Other languages
English (en)
Inventor
Matthew Alexander
Sogole Bahmanyar
John Fredrerick Boylan
Joshua Hansen
Dehua Huang
Robert Hubbard
Brandon Jeffy
Jim Leisten
Mehran Moghaddam
Raj K. Raheja
Heather Raymon
Kimberly Schwarz
Marianne Sloss
Eduardo Torres
Tam Minh Tran
Shuichan Xu
Jingjing Zhao
Original Assignee
Signal Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals, Llc filed Critical Signal Pharmaceuticals, Llc
Publication of CY1124173T1 publication Critical patent/CY1124173T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Στο παρόν παρέχονται Ενώσεις Αμινοπουρίνης που έχουν τις ακόλουθες δομές, όπου τα R1, R2 και R3 είναι όπως ορίζονται στο παρόν, σύνθεση που περιλαμβάνει μία αποτελεσματική ποσότητα μιας Ένωσης Αμινοπουρίνης και μέθοδοι για τη θεραπεία ή την πρόληψη ενός καρκίνου, παραδείγματος χάριν μελανώματος. Παρέχονται στο παρόν ενώσεις που έχουν τον ακόλουθο τύπο (Ι) και φαρμακευτικά αποδεκτά άλατα, ταυτομερή, ισοτοπόλογα και στερεοϊσομερή αυτών, όπου τα R1, R2 και R3 είναι όπως ορίζονται στο παρόν.
CY20211100444T 2014-10-06 2021-05-24 Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες CY1124173T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462060339P 2014-10-06 2014-10-06
PCT/US2015/053941 WO2016057370A1 (en) 2014-10-06 2015-10-05 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
CY1124173T1 true CY1124173T1 (el) 2022-05-27

Family

ID=55632334

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100444T CY1124173T1 (el) 2014-10-06 2021-05-24 Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες

Country Status (28)

Country Link
US (8) US9512124B2 (el)
EP (2) EP3822274B1 (el)
JP (4) JP6884701B2 (el)
KR (2) KR102504849B1 (el)
CN (2) CN113248506A (el)
AR (2) AR102171A1 (el)
AU (2) AU2015328414B2 (el)
CA (1) CA2963639C (el)
CL (1) CL2017000820A1 (el)
CO (1) CO2017003838A2 (el)
CY (1) CY1124173T1 (el)
DK (1) DK3204386T3 (el)
EA (1) EA201790779A1 (el)
EC (1) ECSP17026210A (el)
ES (2) ES2871142T3 (el)
HR (1) HRP20210656T1 (el)
HU (1) HUE054694T2 (el)
IL (2) IL251566B (el)
LT (1) LT3204386T (el)
MX (2) MX388321B (el)
PL (1) PL3204386T3 (el)
PT (1) PT3204386T (el)
RS (1) RS61884B1 (el)
SG (2) SG11201702759XA (el)
SI (1) SI3204386T1 (el)
SM (1) SMT202100302T1 (el)
TW (1) TW201629063A (el)
WO (1) WO2016057370A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963639C (en) * 2014-10-06 2023-07-04 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ，エルエルシー 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10189840B2 (en) 2015-03-18 2019-01-29 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
WO2016149439A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf
EP3271361B1 (en) 2015-03-18 2020-04-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf
CN107922287B (zh) 2015-07-24 2021-04-09 细胞基因公司 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
BR112018001980A2 (pt) 2015-08-03 2018-09-18 Bristol Myers Squibb Co compostos cíclicos úteis como moduladores de tnf alfa
US10047090B2 (en) * 2016-04-01 2018-08-14 Signal Pharmaceuticals, Llc Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
AU2017241837B2 (en) * 2016-04-01 2021-07-22 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
US10010555B2 (en) 2016-06-02 2018-07-03 Celgene Corporation Animal and human anti-trypanosomonal and anti-leishmania agents
EP3464287B1 (en) * 2016-06-02 2022-06-08 Celgene Corporation Animal and human anti-malarial agents
CA3078368A1 (en) * 2017-10-04 2019-04-11 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
US10590136B2 (en) 2017-10-04 2020-03-17 Celgene Corporation Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114478326B (zh) * 2022-01-21 2023-10-03 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US7672705B2 (en) * 2004-07-19 2010-03-02 Resonant Medical, Inc. Weighted surface-to-surface mapping
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
CN101360725B (zh) 2005-11-18 2011-09-21 阿斯利康公司 固体制剂
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
KR20090084891A (ko) 2006-10-27 2009-08-05 시그날 파마소티칼 엘엘씨 4-[9-(테트라하이드로-퓨란-3-일)-8-(2,4,6-트리플루오로-페닐아미노)-9ｈ-퓨린-2-일아미노]-사이클로헥산-1-올을 포함하는 고체 형태들, 이들의 조성물들 및 이들의 용도
EP2279731B1 (en) 2008-04-23 2012-12-12 Farmasierra Manufacturing, S.L. Improved pharmaceutical composition containing ibuprofen and codeine
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CA2963639C (en) * 2014-10-06 2023-07-04 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
US10047090B2 (en) 2016-04-01 2018-08-14 Signal Pharmaceuticals, Llc Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use

Also Published As

Publication number Publication date
EP3204386B1 (en) 2021-03-03
US9512124B2 (en) 2016-12-06
CN107001372B (zh) 2021-04-27
US20210128565A1 (en) 2021-05-06
JP2022033858A (ja) 2022-03-02
US9737541B2 (en) 2017-08-22
BR112017006998A2 (pt) 2018-01-16
CO2017003838A2 (es) 2017-07-11
KR102504849B1 (ko) 2023-03-02
AR102171A1 (es) 2017-02-08
US10398700B2 (en) 2019-09-03
MX388321B (es) 2025-03-19
EA201790779A1 (ru) 2017-09-29
MX2021014531A (es) 2022-01-06
AU2015328414A1 (en) 2017-04-27
LT3204386T (lt) 2021-07-12
EP3822274B1 (en) 2024-03-06
SI3204386T1 (sl) 2021-08-31
TW201629063A (zh) 2016-08-16
CA2963639A1 (en) 2016-04-14
PL3204386T3 (pl) 2021-09-20
KR20230035424A (ko) 2023-03-13
JP2020033352A (ja) 2020-03-05
IL251566B (en) 2020-09-30
AU2020201486A1 (en) 2020-03-19
US20200237768A1 (en) 2020-07-30
EP3204386A4 (en) 2018-04-18
NZ730753A (en) 2024-02-23
JP2017530199A (ja) 2017-10-12
US10646493B2 (en) 2020-05-12
MX2017004600A (es) 2017-06-30
US20190091230A1 (en) 2019-03-28
IL277069A (en) 2020-10-29
US11590139B2 (en) 2023-02-28
CL2017000820A1 (es) 2017-12-15
US20160096841A1 (en) 2016-04-07
US20170042902A1 (en) 2017-02-16
US10149849B2 (en) 2018-12-11
AU2020201486B2 (en) 2021-07-08
US20190336507A1 (en) 2019-11-07
ES2871142T3 (es) 2021-10-28
EP3204386A1 (en) 2017-08-16
HRP20210656T1 (hr) 2021-07-23
US20170296546A1 (en) 2017-10-19
AU2015328414B2 (en) 2020-03-19
ES2980464T3 (es) 2024-10-01
ECSP17026210A (es) 2017-05-31
IL251566A0 (en) 2017-05-29
US20230158035A1 (en) 2023-05-25
JP2023027269A (ja) 2023-03-01
US10940152B2 (en) 2021-03-09
IL277069B (en) 2022-05-01
SG11201702759XA (en) 2017-05-30
AR128748A2 (es) 2024-06-12
DK3204386T3 (da) 2021-05-25
EP3822274A1 (en) 2021-05-19
WO2016057370A1 (en) 2016-04-14
CN113248506A (zh) 2021-08-13
KR20170063740A (ko) 2017-06-08
JP7196270B2 (ja) 2022-12-26
JP6987823B2 (ja) 2022-01-05
RS61884B1 (sr) 2021-06-30
CA2963639C (en) 2023-07-04
NZ767954A (en) 2024-02-23
HUE054694T2 (hu) 2021-09-28
PT3204386T (pt) 2021-05-31
SG10202009598VA (en) 2020-10-29
JP6884701B2 (ja) 2021-06-09
CN107001372A (zh) 2017-08-01
SMT202100302T1 (it) 2021-07-12

Similar Documents

Publication Publication Date Title
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
CY1122340T1 (el) Αντιπολλαπλασιαστικες ενωσεις και μεθοδοι χρησης αυτων
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1125230T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1121901T1 (el) Ενωσεις τριαζολοπυριμιδινης και χρησεις αυτων
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1123451T1 (el) Αγωνιστες τριαζολης του υποδοχεα αρj
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CL2021000175A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
MX376106B (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b.
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
CY1125198T1 (el) Ενωσεις και αναλογα 1-ετεροκυκλικου ισοχρωμανυλιου για την αντιμετωπιση διαταραχων του κνς
CY1121884T1 (el) Αντι-ογκικες ενωσεις
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos